Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on KalVista Pharmaceuticals (KALV – Research Report), with a price target of $20.00.
Andrew Fein’s rating is based on the promising potential of sebetralstat, KalVista Pharmaceuticals’ oral on-demand therapy for hereditary angioedema (HAE). The drug is positioned as a convenient and effective alternative to the currently approved on-demand treatments, which require parenteral administration and are often associated with treatment delays. With the PDUFA date set for June 2025, Fein anticipates a strong launch for sebetralstat, driven by its ability to offer a pain-free and faster treatment option for HAE attacks.
Fein highlights that despite advancements in prophylactic treatments, the demand for on-demand therapies remains robust, as nearly half of prophylactic patients still experience breakthrough attacks. The Phase 3 KONFIDENT trial data supports the efficacy of sebetralstat, showing that earlier treatment leads to faster resolution and potentially milder attacks. This positions sebetralstat as a significant improvement over existing therapies, addressing a critical unmet need in the HAE treatment landscape, and justifying Fein’s Buy rating for KalVista Pharmaceuticals.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALV in relation to earlier this year.